Medical science and technology fields have always been intertwined, but a new strategic collaboration between neurostimulation technology specialist NeuroPace and medical research firm Rapport is set to take this synergy to new heights. The partnership aims to study the effects of a novel therapy for focal epilepsy, a neurological condition that affects millions globally.

Unleashing the Power of Responsive Neurostimulation

The collaboration will leverage NeuroPace’s groundbreaking Responsive Neurostimulation System (RNS), an FDA-approved treatment for medically refractory epilepsy. The RNS System is implanted in patients participating in a phase 2a proof-of-concept study for Rapport’s treatment candidate, RAP-219. It monitors and analyzes biomarker changes in these patients, providing invaluable data about the effects of the new therapy.

Big Data and AI: Future of Personalized Epilepsy Treatments

In an interview with NeurologyLive, Dr. Martha Morrell, a neurology professor at Stanford University School of Medicine and Chief Medical Officer at NeuroPace, spoke about the significant role of big data and artificial intelligence in this collaboration. She stressed that these technologies are crucial in personalizing epilepsy treatments, advancing therapy options, and addressing the challenges in the field.

A Shift in Epilepsy Treatment Approach

This partnership represents a paradigm shift in study designs for epilepsy treatments, moving away from traditional methods. The collaboration aims to evaluate the impact of RAP-219 on focal onset seizures, a common form of epilepsy, by harnessing the power of data insights provided by NeuroPace’s RNS System. By focusing on patient-specific biomarker changes, the team is positioning itself at the forefront of personalized epilepsy treatment.


Source:, Mahnoor Jehangir